Skip to content

Study · Animal study (in vivo) · mouse · 2015

7 results

Neuro-peptide treatment with Cerebrolysin improves the survival of neural stem cell grafts in an APP transgenic model of Alzheimer disease.

Rockenstein E, Desplats P, Ubhi K, Mante M, Florio J, Adame A, Winter S, Brandstaetter H, Meier D, Masliah E

Stem cell research9 May 2015Cited by 33 (Europe PMC)

PMID26209890 (opens in a new tab)DOI10.1016/j.scr.2015.04.008 (opens in a new tab)PepBankPUB-26209890
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In non-tg mice with neural stem cell grafts, Cerebrolysin enhanced grafted cell survival compared with vehicle treatment.

    In plain wordsIn mice without the transgene, Cerebrolysin increased grafted neural stem cell survival compared with vehicle treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseGrafted NSC survival in non-tg mice
    Study

    mousen: not reported in source

    Murine neural stem cell grafts in non-tg and APP transgenic mice
    Comparator
    Vehicle-treated mice with neural stem cell grafts
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Whereas, CBL treatment enhanced the survival of NSCs in both non-tg and APP tg with the majority of the surviving NSCs remaining as neuroblasts.
    2 context sentences
    Summary · context
    In this context, we investigated the utility of Cerebrolysin (CBL), a peptidergic mixture with neurotrophic-like properties, as an adjunct to stem cell therapy in an APP transgenic (tg) model of AD.
    Summary · context
    We grafted murine NSCs into the hippocampus of non-tg and APP tg that were treated systemically with CBL and analyzed after 1, 3, 6 and 9months post grafting.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In APP transgenic mice with neural stem cell grafts, Cerebrolysin enhanced grafted cell survival compared with vehicle treatment.

    In plain wordsIn APP transgenic mice, Cerebrolysin increased grafted neural stem cell survival compared with vehicle treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseGrafted NSC survival in APP tg mice
    Study

    mousen: not reported in source

    Murine neural stem cell grafts in non-tg and APP transgenic mice
    Comparator
    Vehicle-treated mice with neural stem cell grafts
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Whereas, CBL treatment enhanced the survival of NSCs in both non-tg and APP tg with the majority of the surviving NSCs remaining as neuroblasts.
    2 context sentences
    Summary · context
    In this context, we investigated the utility of Cerebrolysin (CBL), a peptidergic mixture with neurotrophic-like properties, as an adjunct to stem cell therapy in an APP transgenic (tg) model of AD.
    Summary · context
    We grafted murine NSCs into the hippocampus of non-tg and APP tg that were treated systemically with CBL and analyzed after 1, 3, 6 and 9months post grafting.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In Cerebrolysin-treated mice with neural stem cell grafts, most surviving NSCs remained neuroblasts.

    In plain wordsIn mice treated with Cerebrolysin, most surviving grafted neural stem cells remained neuroblasts.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableSurviving NSC differentiation state
    Study

    mousen: not reported in source

    Murine neural stem cell grafts in non-tg and APP transgenic mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Whereas, CBL treatment enhanced the survival of NSCs in both non-tg and APP tg with the majority of the surviving NSCs remaining as neuroblasts.
    2 context sentences
    Summary · context
    In this context, we investigated the utility of Cerebrolysin (CBL), a peptidergic mixture with neurotrophic-like properties, as an adjunct to stem cell therapy in an APP transgenic (tg) model of AD.
    Summary · context
    We grafted murine NSCs into the hippocampus of non-tg and APP tg that were treated systemically with CBL and analyzed after 1, 3, 6 and 9months post grafting.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with neural stem cell grafts, Cerebrolysin treatment reduced numbers of caspase-3 positive grafted cells.

    In plain wordsIn mice with neural stem cell grafts, Cerebrolysin reduced caspase-3 positive grafted cells compared with vehicle treatment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseCaspase-3 positive grafted cells
    Study

    mousen: not reported in source

    Murine neural stem cell grafts in non-tg and APP transgenic mice
    Comparator
    Vehicle-treated mice with neural stem cell grafts
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    The NSCs of the CBL treated mice displayed reduced numbers of caspase-3 and TUNEL positive cells and increased brain derived neurotrophic factor (BDNF) and furin immunoreactivity.
    2 context sentences
    Summary · context
    In this context, we investigated the utility of Cerebrolysin (CBL), a peptidergic mixture with neurotrophic-like properties, as an adjunct to stem cell therapy in an APP transgenic (tg) model of AD.
    Summary · context
    We grafted murine NSCs into the hippocampus of non-tg and APP tg that were treated systemically with CBL and analyzed after 1, 3, 6 and 9months post grafting.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice with neural stem cell grafts, Cerebrolysin treatment reduced numbers of TUNEL positive grafted cells.

    In plain wordsIn mice with neural stem cell grafts, Cerebrolysin reduced TUNEL positive grafted cells compared with vehicle treatment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseTUNEL positive grafted cells
    Study

    mousen: not reported in source

    Murine neural stem cell grafts in non-tg and APP transgenic mice
    Comparator
    Vehicle-treated mice with neural stem cell grafts
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    The NSCs of the CBL treated mice displayed reduced numbers of caspase-3 and TUNEL positive cells and increased brain derived neurotrophic factor (BDNF) and furin immunoreactivity.
    2 context sentences
    Summary · context
    In this context, we investigated the utility of Cerebrolysin (CBL), a peptidergic mixture with neurotrophic-like properties, as an adjunct to stem cell therapy in an APP transgenic (tg) model of AD.
    Summary · context
    We grafted murine NSCs into the hippocampus of non-tg and APP tg that were treated systemically with CBL and analyzed after 1, 3, 6 and 9months post grafting.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In mice with neural stem cell grafts, Cerebrolysin treatment increased BDNF immunoreactivity in grafted NSCs.

    In plain wordsIn mice with neural stem cell grafts, Cerebrolysin increased BDNF immunoreactivity compared with vehicle treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseBDNF immunoreactivity
    Study

    mousen: not reported in source

    Murine neural stem cell grafts in non-tg and APP transgenic mice
    Comparator
    Vehicle-treated mice with neural stem cell grafts
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    The NSCs of the CBL treated mice displayed reduced numbers of caspase-3 and TUNEL positive cells and increased brain derived neurotrophic factor (BDNF) and furin immunoreactivity.
    2 context sentences
    Summary · context
    In this context, we investigated the utility of Cerebrolysin (CBL), a peptidergic mixture with neurotrophic-like properties, as an adjunct to stem cell therapy in an APP transgenic (tg) model of AD.
    Summary · context
    We grafted murine NSCs into the hippocampus of non-tg and APP tg that were treated systemically with CBL and analyzed after 1, 3, 6 and 9months post grafting.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In mice with neural stem cell grafts, Cerebrolysin treatment increased furin immunoreactivity in grafted NSCs.

    In plain wordsIn mice with neural stem cell grafts, Cerebrolysin increased furin immunoreactivity compared with vehicle treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseFurin immunoreactivity
    Study

    mousen: not reported in source

    Murine neural stem cell grafts in non-tg and APP transgenic mice
    Comparator
    Vehicle-treated mice with neural stem cell grafts
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    The NSCs of the CBL treated mice displayed reduced numbers of caspase-3 and TUNEL positive cells and increased brain derived neurotrophic factor (BDNF) and furin immunoreactivity.
    2 context sentences
    Summary · context
    In this context, we investigated the utility of Cerebrolysin (CBL), a peptidergic mixture with neurotrophic-like properties, as an adjunct to stem cell therapy in an APP transgenic (tg) model of AD.
    Summary · context
    We grafted murine NSCs into the hippocampus of non-tg and APP tg that were treated systemically with CBL and analyzed after 1, 3, 6 and 9months post grafting.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.